Ipsen is buying U.S. blood cancer startup Kartos for up to $1.75 billion
The French drugmaker is paying $450 million upfront for Kartos, which is developing a late-stage myelofibrosis drug
Overview
The French drugmaker is paying $450 million upfront for Kartos, which is developing a late-stage myelofibrosis drug
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
